Marta Giussani

Dr. Marta Giussani

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Seminars in Cancer Biology
Verified
Journal Article
Open access
MGMarta Giussani
Marta Giussani
GMGiuseppe Merlino
Giuseppe Merlino
VCVera Cappelletti
Vera Cappelletti
Elda TagliabueElda Tagliabue
Elda Tagliabue
MDMaria Grazia Daidone
Maria Grazia Daidone
Several evidences support the concept that cancer development and progression are not entirely cancer cell-autonomous processes, but may be influenced, and possibly driven, by cross-talk between cancer cells and the surrounding microenvironment in which, besides immune cells, stromal cells and extracellular matrix (ECM) play a major role in regulating distinct biologic processes. Stroma and ECM-related signatures proved to influence breast cancer progression, and to contribute to the identification of tumor phenotypes resistant to cytotoxic and hormonal treatments. The possible clinical implications of the interplay between tumor cells and the microenvironment, with special reference to ECM remodelling, will be discussed in this review.

23 January 2019 in Cells
Verified
Journal Article
Open access
PDF file
MGMarta Giussani
Marta Giussani
Tiziana TriulziTiziana Triulzi
Tiziana Triulzi
GSgabriella sozzi
gabriella sozzi
Elda TagliabueElda Tagliabue
Elda Tagliabue
In recent years, it has become increasingly evident that cancer cells and the local microenvironment are crucial in the development and progression of tumors. One of the major components of the tumor microenvironment is the extracellular matrix (ECM), which comprises a complex mixture of components, including proteins, glycoproteins, proteoglycans, and polysaccharides. In addition to providing structural and biochemical support to tumor tissue, the ECM undergoes remodeling that alters the biochemical and mechanical properties of the tumor microenvironment and contributes to tumor progression and resistance to therapy. A novel concept has emerged, in which tumor-driven ECM remodeling affects the release of ECM components into peripheral blood, the levels of which are potential diagnostic or prognostic markers for tumors. This review discusses the most recent evidence on ECM remodeling-derived signals that are detectable in the bloodstream, as new early diagnostic and risk prediction tools for the most frequent solid cancers.

9 March 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MGMarta Giussani
Marta Giussani
ELElena Landoni
Elena Landoni
GMGiuseppe Merlino
Giuseppe Merlino
FTFederica Turdo
Federica Turdo
SVSilvia Veneroni
Silvia Veneroni
Elda TagliabueElda Tagliabue
Elda Tagliabue

18 September 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FAFrancesca Andriani
Francesca Andriani
ELElena Landoni
Elena Landoni
MMMavis Mensah
Mavis Mensah
FFFederica Facchinetti
Federica Facchinetti
RMRosalba Miceli
Rosalba Miceli
GSgabriella sozzi
gabriella sozzi
Interactions between cancer cells and the surrounding microenvironment are crucial determinants of cancer progression. During this process, bi-directional communication among tumor cells and cancer associated fibroblasts (CAF) regulate extracellular matrix (ECM) deposition and remodeling. As a result of this dynamic process, soluble ECM proteins can be released into the bloodstream and may represent novel circulating biomarkers useful for cancer diagnosis. The aim of the present study was to measure the levels of three circulating ECM related proteins (COL11A1, COL10A1 and SPARC) in plasma samples of lung cancer patients and in healthy heavy-smokers controls and test whether such measurements have diagnostic or prognostic value. Gene expression profiling of lung fibroblasts isolated from paired normal and cancer tissue of NSCLC patients was performed by gene expression microarrays. The prioritization of the candidates for the study of circulating proteins in plasma was based on the most differentially expressed genes in cancer associated fibroblasts. Soluble ECM proteins were assessed by western blot in the conditioned medium of lung fibroblasts and by ELISA assays in plasma samples. Plasma samples from lung cancer patients and healthy heavy-smokers controls were tested for levels of COL11A1 and COL10A1 (n = 57 each) and SPARC (n = 90 each). Higher plasma levels of COL10A1 were detected in patients (p ≤ 0.001), a difference that was driven specifically by females (p < 0.001). No difference in COL11A1 levels between patients and controls was found. SPARC levels were also higher in plasma patients than controls (p < 0.001) with good performance in discriminating the two groups (AUC = 0.744). No significant association was observed between plasma proteins levels and clinicopathological features or survival. Soluble factors related to proficient tumor-stroma cross-talk are detectable in plasma of primary lung cancer patients and may represent a valuable complementary diagnostic tool to discriminate lung cancer patients from healthy heavy-smokers individuals as shown for the SPARC protein.

1 July 2015 in Oncotarget
Verified
Journal Article
Open access
Tiziana TriulziTiziana Triulzi
Tiziana Triulzi
LCLoris De cecco
Loris De cecco
Marco SandriMarco Sandri
Marco Sandri
APAleix Prat
Aleix Prat
MGMarta Giussani
Marta Giussani
Elda TagliabueElda Tagliabue
Elda Tagliabue
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

23 February 2020 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
ARAnna Rossini
Anna Rossini
MGMarta Giussani
Marta Giussani
FRFrancesca Ripamonti
Francesca Ripamonti
PAPiera Aiello
Piera Aiello
VRViola Regondi
Viola Regondi
Elda TagliabueElda Tagliabue
Elda Tagliabue
Progression of prostate cancer has been associated with EGFR and HER2 activation and to tumor-initiating cells contribution toward chemotherapy resistance. We investigated the efficacy of a dual intervention against EGFR and HER2 to deplete the tumor-initiating cells, optimize the chemotherapy management and prevent the progression of castration-resistant prostate cancer (CRPC) cells. Using DU145, PC3, and 22Rv1 CRPC cell lines, biochemical analysis revealed activation of EGFR, HER2, MAPK, and STAT3 in DU145 and 22Rv1, and AKT and SRC in DU145 and PC-3. pSTAT3 nuclear staining was observed in DU145 xenografts and in 12 out of 14 CRPC specimens. The in vivo dual targeting of ErbB receptors with Cetuximab and Trastuzumab combined with chemotherapy caused an effective antitumor response in DU145 xenografted mice displaying STAT3 activation; conversely PC-3 bearing mice experienced tumor relapse. The potentiating of in vivo cytotoxic effect in DU145 model was accompanied by a significant decrease of prostatosphere-forming capacity assessed in vitro on residual tumor cells. Additionally, combined treatment in vitro with Cetuximab, Trastuzumab and chemotherapy negatively affected DU145 and 22Rv1 sphere formation, suggesting the critical function of ErbB receptors for tumor-initiating cells proliferation; no effect on PC-3 clonogenic potential was observed, indicating that other receptors than EGFR and HER2 may sustain PC3 tumor-initiating cells. These findings provided the preclinical evidence that the dual inhibition of EGFR and HER2 by targeting tumor-initiating cells may improve the efficacy of the current chemotherapy regimen, bringing benefits especially to castration-resistant patients with activated STAT3, and preventing disease progression.